in vitro News and Research

RSS

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

New data shows that gut microbiota has potential role in development of ALD

Exciting new data presented today at the International Liver Congress- 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).

15 Apr 2014

Researchers identify eight new active molecules against Alzheimer

Researchers of the Unit of Medicine Design and Molecular Topology (Department of Physics Chemistry) of the University of Valencia have discovered eight new active molecules against Alzheimer by a novel mechanism of action, different to the currently used medicines. The work has just been published in the "Plos One" magazine.

11 Apr 2014

Researchers discover tumor suppressor gene folliculin essential to normal lung function in BHD patients

11 Apr 2014

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.

11 Apr 2014

Human testes respond differently to endocrine disrupting chemicals

Human and rat testes respond differently to endocrine disrupting chemicals such as BPA in two thirds of all cases, according to a recent review. As human safety levels are extrapolated from rodent data, the study could lead to a re-evaluation of the acceptable daily intake for many endocrine disruptors.

10 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Inserm plays key role in developing European research

The French National Institute of Health and Medical Research (Inserm) is currently the leading biomedical research organisation in Europe, and plays a key role in developing European research. To mark its 50th anniversary, Inserm wanted to assess the perceptions of Europeans regarding biomedical research.

10 Apr 2014

New discovery opens door to development of new treatments that stop progression of Parkinson's disease

A research led by the Research Institute Vall d'Hebron (VHIR), in which the University of Valencia participated, has shown that pathological forms of the α-synuclein protein present in deceased patients with Parkinson's disease are able to initiate and spread in mice and primates the neurodegenerative process that typifies this disease.

10 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Red LED irradiation promotes cell transplantation in treatment of hypoxic-ischemic brain damage

A series of previous studies suggested that the neuronal differentiation rate of bone marrow mesenchymal stem cells during the in vitro culture reached 78-92%, but their in vivo transplantation efficiency, and survival and differentiation rates were very low.

10 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Low-dose aspirin not significantly associated with pregnancy loss

The Effects of Aspirin in Gestation and Reproduction (EAGeR) medical trial has found that, in general, low-dose aspirin is not beneficial for future pregnancy outcomes in women with prior pregnancy loss.

7 Apr 2014

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research, April 5-9, 2014 in San Diego, CA.

4 Apr 2014

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.

3 Apr 2014

AB Sciex launches immunosuppressants kit to improve health care

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection.

2 Apr 2014

in vitro News and Research

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

New data shows that gut microbiota has potential role in development of ALD

Researchers identify eight new active molecules against Alzheimer

Researchers discover tumor suppressor gene folliculin essential to normal lung function in BHD patients

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Human testes respond differently to endocrine disrupting chemicals

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Inserm plays key role in developing European research

New discovery opens door to development of new treatments that stop progression of Parkinson's disease

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Red LED irradiation promotes cell transplantation in treatment of hypoxic-ischemic brain damage

Researchers identify novel compound effective against drug-resistant lung cancer

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

Low-dose aspirin not significantly associated with pregnancy loss

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

AB Sciex launches immunosuppressants kit to improve health care

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News